Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $16.0 million.

  • Rxo's Capital Expenditures rose 3333.33% to $16.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $59.0 million, marking a year-over-year increase of 3111.11%. This contributed to the annual value of $59.0 million for FY2025, which is 3111.11% up from last year.
  • Rxo's Capital Expenditures amounted to $16.0 million in Q4 2025, which was up 3333.33% from $14.0 million recorded in Q3 2025.
  • Rxo's 5-year Capital Expenditures high stood at $18.0 million for Q4 2022, and its period low was $9.0 million during Q4 2021.
  • Moreover, its 5-year median value for Capital Expenditures was $14.0 million (2025), whereas its average is $13.8 million.
  • In the last 5 years, Rxo's Capital Expenditures surged by 10000.0% in 2022 and then crashed by 3888.89% in 2024.
  • Quarter analysis of 5 years shows Rxo's Capital Expenditures stood at $9.0 million in 2021, then surged by 100.0% to $18.0 million in 2022, then changed by 0.0% to $18.0 million in 2023, then crashed by 33.33% to $12.0 million in 2024, then surged by 33.33% to $16.0 million in 2025.
  • Its Capital Expenditures stands at $16.0 million for Q4 2025, versus $14.0 million for Q3 2025 and $14.0 million for Q2 2025.